--- title: "Fractyl Health | 8-K: FY2026 Q2 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/295444068.md" datetime: "2026-08-10T20:08:17.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295444068.md) - [en](https://longbridge.com/en/news/295444068.md) - [zh-HK](https://longbridge.com/zh-HK/news/295444068.md) generator: "portal-rs" --- # Fractyl Health | 8-K: FY2026 Q2 Revenue: USD 0 Revenue: As of FY2026 Q2, the actual value is USD 0. EPS: As of FY2026 Q2, the actual value is USD -0.16. EBIT: As of FY2026 Q2, the actual value is USD -18.67 M. ### Financial Results for the Quarter Ended June 30, 2026 #### Operating Expenses - **Research and Development Expenses**: Fractyl Health, Inc. reported $13.8 million, a decrease from $21.2 million in the same period of 2025, primarily due to reduced spending on Revita and Rejuva programs. - **Selling, General and Administrative Expenses**: SG&A expenses were $5.3 million, an increase from $4.9 million in the same period of 2025, mainly driven by higher stock compensation expenses. - **Total Operating Expenses**: Total operating expenses were $19.1 million, down from $26.1 million in the prior year period. #### Profitability - **Loss from Operations**: The loss from operations was - $19.1 million, compared to - $26.1 million for the same period in 2025. - **Net Loss**: Fractyl Health, Inc. reported a net loss of - $25.5 million, a decrease from a net loss of - $27.9 million in the same period of 2025. - **Adjusted EBITDA**: Adjusted EBITDA was - $16.3 million, an improvement from - $24.0 million in the same period of 2025, primarily due to reduced operating expenses excluding stock compensation expenses. #### Other Income (Expense), Net - **Interest Income, Net**: $0.4 million, compared to $0.2 million for the same period in 2025. - **Change in fair value of notes payable**: - $1.4 million, compared to - $1.7 million for the same period in 2025. - **Change in fair value of warrant liabilities**: - $5.5 million, compared to - $0.3 million for the same period in 2025. - **Total other income (expense), net**: - $6.4 million, compared to - $1.8 million for the same period in 2025. ### Financial Results for the Six Months Ended June 30, 2026 #### Operating Expenses - **Research and Development Expenses**: $29.4 million, compared to $40.6 million for the same period in 2025. - **Selling, General and Administrative Expenses**: $10.5 million, compared to $10.3 million for the same period in 2025. - **Total Operating Expenses**: Total operating expenses were $39.9 million, down from $50.8 million in the prior year period. #### Profitability - **Loss from Operations**: The loss from operations was - $39.9 million, compared to - $50.8 million for the same period in 2025. - **Net Loss**: Fractyl Health, Inc. reported a net loss of - $16.3 million, compared to - $51.6 million for the same period in 2025. - **Adjusted EBITDA**: Adjusted EBITDA was - $34.3 million, compared to - $47.1 million for the same period in 2025. #### Other Income (Expense), Net - **Interest Income, Net**: $1.0 million, compared to $0.7 million for the same period in 2025. - **Change in fair value of notes payable**: - $2.0 million, compared to - $2.0 million for the same period in 2025. - **Change in fair value of warrant liabilities**: $24.6 million, compared to $0.5 million for the same period in 2025. - **Total other income (expense), net**: $23.6 million, compared to - $0.8 million for the same period in 2025. ### Balance Sheet Highlights (as of June 30, 2026) - **Cash and cash equivalents**: $47.1 million, down from $81.5 million as of December 31, 2025. - **Restricted cash**: $4.3 million, unchanged from December 31, 2025. - **Working capital**: $33.9 million, compared to $69.2 million as of December 31, 2025. - **Total assets**: $82.0 million, compared to $121.4 million as of December 31, 2025. - **Notes payable, long-term**: $30.4 million, compared to $30.6 million as of December 31, 2025. - **Total liabilities**: $83.6 million, compared to $111.9 million as of December 31, 2025. - **Total stockholders’ equity (deficit)**: - $1.7 million, compared to $9.5 million as of December 31, 2025. ### Operational Metrics - **REMAIN-1 Midpoint Cohort Data**: One-year data indicated Revita patients maintained up to 84% of prior GLP-1-induced weight loss, versus 46% with sham, in patients receiving complete duodenal ablations. - **REVEAL-1 Cohort Data**: One-year open-label data showed patients maintained approximately 78% of their prior GLP-1-induced weight loss after a single Revita procedure, with a mean total body weight change of 5.3% after GLP-1 discontinuation. ### Outlook and Guidance Fractyl Health, Inc. reiterated its cash runway guidance into early 2027, extending beyond the anticipated pivotal data readout and FDA De Novo Submission. The company expects topline 6-month randomized data from the REMAIN-1 Pivotal Cohort in early Q4 2026, with a potential FDA De Novo marketing application submission in late Q4 2026 for post-GLP-1 weight maintenance. For its Rejuva program, the first-in-human dosing of RJVA-001 and preliminary data reporting are anticipated in H2 2026, subject to site activation. ### Related Stocks - [GUTS.US](https://longbridge.com/en/quote/GUTS.US.md) ## Related News & Research - [Fractyl Health to host virtual Commercial Strategy Day on Revita go-to-market plan](https://longbridge.com/en/news/296479388.md) - [Fractyl Health spotlights REMAIN-1 data showing Revita maintains 84% of GLP-1 weight loss in optimized cohort](https://longbridge.com/en/news/296481537.md) - [SelectQuote Q4 2026 Earnings Preview](https://longbridge.com/en/news/296823343.md) - [Fractyl Health Earnings Call Signals Promise Amid Risks](https://longbridge.com/en/news/296690642.md) - [Xcel Energy sets BRL 0.26 per unit distribution for payment Oct. 26, 2026](https://longbridge.com/en/news/296646864.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**